2CB-2-EtO

2CB-2-EtO, also known as 4-bromo-2-methoxy-5-ethoxyphenethylamine, is a psychedelic drug of the phenethylamine, 2C, and TWEETIO families related to 2C-B. It is the derivative of 2C-B in which the methoxy group at the 2 position has been replaced with an ethoxy group. According to Alexander Shulgin in his book PiHKAL and other publications, 2CB-2-EtO produces maximal effects at a dose of about 15mg orally. Higher doses of 30 to 50mg orally did not increase its effects any further but only prolonged their duration, from about 3hours to perhaps 6hours. 2CB-2-EtO was said to have not had an intensity that resembled that of 2C-B at any dose. It was also said to be dramatically or about 5-fold less potent than 2C-B. The chemical synthesis of 2CB-2-EtO has been described. The drug was first described in the literature by Shulgin in PiHKAL in 1991. It was developed and tested by Darrell Lemaire, with publication via personal communication with Shulgin. The drug is a controlled substance in Canada under phenethylamine blanket-ban language.